Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment

BACKGROUND: Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyrie, Sabrina, Fauquet, Isabelle, Rives, Michel, Genebes, Caroline, Delord, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Case Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872282/
https://www.ncbi.nlm.nih.gov/pubmed/24386625
http://dx.doi.org/10.1186/2193-1801-2-679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872282/
https://www.ncbi.nlm.nih.gov/pubmed/24386625
http://dx.doi.org/10.1186/2193-1801-2-679

Ejemplares similares